Faruqi and Faruqui, LLP Logo
Share this page

Synageva BioPharma, Inc. (GEVA)

(Nasdaq: GEVA)


SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Synageva BioPharma Corp. Over the Proposed Sale of the Company to Alexion Pharmaceuticals, Inc.- GEVA

May 7, 2015 – Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc. (“Synageva” or the “Company”) (Nasdaq: GEVA) for potential breaches of fiduciary duties in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. (“Alexion”) (Nasdaq: ALXN) for approximately $8.4 billion in a cash and stock transaction. The deal gives Synageva shares a total value of $226; $115 of which will be paid in cash, while the remaining $111 will be paid for in Alexion stock.

The investigation focuses on whether Synageva’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Synageva’s shareholders.

If you own common stock in Synageva and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Synageva BioPharma, Inc. (GEVA)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Juan E. Monteverde
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 05/07/2015

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.